Alvotech says FDA accepts AVT80 biosimilar application for review
ALVO•FDA accepts AVT80 biosimilar application for review
- FDA accepted for review a BLA for AVT80, Alvotech’s proposed interchangeable biosimilar to Entyvio for subcutaneous administration.
- Teva will handle commercialization under the partners’ agreement.
